A Preclinical Population Pharmacokinetic Model for Anti-CD20/CD3 T-Cell-Dependent Bispecific Antibodies.

Clin Transl Sci · 2018 · PMC5944627 · PMID 29351372

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

32 A clear trend emerged when we compared population modeling analyses across these four molecules (rituximab, obinutuzumab, ocrelizumab, and ofatumumab) and five therapeutic indications (NHL, CLL, RA, FL, and MS).

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.